Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAXNASDAQ:FSTXNASDAQ:KROSNASDAQ:ORIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$10.84-6.3%$12.40$7.80▼$28.09$630.98MN/A583,377 shs443,114 shsFSTXF-star Therapeutics$7.12$6.19$2.07▼$7.12$156.50M0.85709,213 shsN/AKROSKeros Therapeutics$13.56-0.6%$13.81$9.12▼$72.37$550.74M1.31863,238 shs377,905 shsORICORIC Pharmaceuticals$9.63-0.4%$6.15$3.90▼$14.67$820.71M1.49774,142 shs714,124 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics-6.31%-5.74%-20.88%-12.72%+1,083,999,900.00%FSTXF-star Therapeutics0.00%0.00%0.00%0.00%0.00%KROSKeros Therapeutics-0.59%-9.84%-0.22%+17.10%-72.32%ORICORIC Pharmaceuticals-0.41%+3.33%+98.15%+23.62%+21.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCAXBicara Therapeutics2.0603 of 5 stars3.50.00.00.02.60.80.6FSTXF-star TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKROSKeros Therapeutics3.6221 of 5 stars4.33.00.00.01.95.00.0ORICORIC Pharmaceuticals3.8526 of 5 stars3.50.00.04.32.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 3.00Buy$31.86193.90% UpsideFSTXF-star Therapeutics 0.00N/AN/AN/AKROSKeros Therapeutics 2.50Moderate Buy$30.56125.34% UpsideORICORIC Pharmaceuticals 3.00Buy$19.1799.03% UpsideCurrent Analyst Ratings BreakdownLatest FSTX, KROS, BCAX, and ORIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025KROSKeros TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$32.00 ➝ $18.005/30/2025KROSKeros TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$15.005/29/2025ORICORIC PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.005/23/2025BCAXBicara TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$8.005/23/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.005/16/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $41.005/12/2025KROSKeros TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$41.00 ➝ $26.005/8/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $25.005/6/2025ORICORIC PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $12.005/6/2025ORICORIC PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/5/2025ORICORIC PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/AN/AN/AFSTXF-star Therapeutics$21.17M7.39N/AN/A$4.70 per share1.51KROSKeros Therapeutics$214.71M2.57N/AN/A$11.09 per share1.22ORICORIC PharmaceuticalsN/AN/AN/AN/A$3.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara TherapeuticsN/AN/A0.00N/AN/AN/AN/AN/A6/26/2025 (Estimated)FSTXF-star Therapeutics-$31.28M-$1.82N/AN/AN/AN/A-57.08%-42.40%N/AKROSKeros Therapeutics-$152.99M-$0.18N/AN/AN/A-27,890.94%-41.74%-38.42%8/6/2025 (Estimated)ORICORIC Pharmaceuticals-$100.70M-$1.87N/AN/AN/AN/A-44.54%-40.72%8/11/2025 (Estimated)Latest FSTX, KROS, BCAX, and ORIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BCAXBicara Therapeutics-$0.40-$0.68-$0.28-$0.68N/AN/A5/6/2025Q1 2025KROSKeros Therapeutics-$0.01$3.62+$3.63$3.62$84.62 million$211.25 million5/5/2025Q1 2025ORICORIC Pharmaceuticals-$0.51-$0.42+$0.09-$0.42N/AN/A3/27/2025Q4 2024BCAXBicara Therapeutics-$0.31-$0.39-$0.08-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/AFSTXF-star TherapeuticsN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/AORICORIC PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/AN/AN/AFSTXF-star Therapeutics0.153.383.38KROSKeros TherapeuticsN/A19.0319.03ORICORIC PharmaceuticalsN/A10.5613.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/AFSTXF-star Therapeutics31.50%KROSKeros Therapeutics71.56%ORICORIC Pharmaceuticals95.05%Insider OwnershipCompanyInsider OwnershipBCAXBicara Therapeutics15.50%FSTXF-star Therapeutics3.20%KROSKeros Therapeutics20.60%ORICORIC Pharmaceuticals6.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3254.54 millionN/AN/AFSTXF-star Therapeutics8421.98 million21.28 millionNot OptionableKROSKeros Therapeutics10040.62 million31.23 millionOptionableORICORIC Pharmaceuticals8085.22 million67.09 millionOptionableFSTX, KROS, BCAX, and ORIC HeadlinesRecent News About These CompaniesORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down After Insider SellingJune 14 at 2:12 AM | americanbankingnews.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $19.17 Average PT from AnalystsJune 14 at 1:29 AM | americanbankingnews.comWhat Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?June 13 at 1:01 PM | zacks.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down on Insider SellingJune 12 at 10:27 AM | marketbeat.comMillennium Management LLC Trims Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)June 12 at 3:08 AM | marketbeat.comBrokers Issue Forecasts for ORIC FY2026 EarningsJune 12 at 1:45 AM | americanbankingnews.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 2,976 SharesJune 11 at 8:50 PM | marketbeat.comOric Pharmaceuticals files to sell 19.23M shares of common stock by selling shareholdersJune 11 at 7:33 PM | msn.comCantor Fitzgerald Weighs in on ORIC FY2026 EarningsJune 11 at 8:45 AM | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from AnalystsJune 11 at 2:06 AM | marketbeat.comInsider Selling: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells 2,600 Shares of StockJune 10, 2025 | insidertrades.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $26,026.00 in StockJune 9, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Bank of America Corp DEJune 8, 2025 | marketbeat.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Still a Buy?June 6, 2025 | marketbeat.comTwo Sigma Investments LP Decreases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)June 6, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 7.6% Higher - Still a Buy?June 4, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 3.5% - Should You Sell?June 3, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume Increase - Time to Buy?June 3, 2025 | marketbeat.comWall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should KnowJune 2, 2025 | zacks.comResearch Analysts Set Expectations for ORIC FY2025 EarningsJune 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFSTX, KROS, BCAX, and ORIC Company DescriptionsBicara Therapeutics NASDAQ:BCAX$10.84 -0.73 (-6.31%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$10.90 +0.06 (+0.60%) As of 06/13/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.F-star Therapeutics NASDAQ:FSTXF-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.Keros Therapeutics NASDAQ:KROS$13.56 -0.08 (-0.59%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$13.75 +0.19 (+1.43%) As of 06/13/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.ORIC Pharmaceuticals NASDAQ:ORIC$9.63 -0.04 (-0.41%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.62 -0.01 (-0.05%) As of 06/13/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
